Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5794598 | 0.98 | HSD11B1 (0.48) | HSD11B1APPCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL42559 | 0.92 | LMNA (0.53) | HSD11B1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL10002400 | 0.92 | LMNA (0.49) | HSD11B1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3842811 | 0.90 | LMNA (0.55) | HSD11B1LMNAHDAC1ALDH1A1 | |
| SCHEMBL2701756 | 0.87 | ALOX5 (0.49) | HSD11B1OPRM1OPRD1OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL8353580 | 0.86 | HSD11B1 (0.46) | HSD11B1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL12227097 | 0.84 | OPRM1 (0.62) | HSD11B1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL3970990 | 0.83 | HSD11B1 (0.49) | HSD11B1APPCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19817411 | 0.82 | IDO1 (0.43) | HSD11B1CYP2C9OPRM1OPRD1OPRK1 | |
| SCHEMBL20491252 | 0.82 | HSD11B1 (0.47) | HSD11B1OPRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110240563-A | A kind of rich preparation method for Buddhist nun of card | 南京法恩化学有限公司 | 2019-09-17 | — | — | CN | claimed |
| CN-108264482-A | It is a kind of to block the rich preparation method for Buddhist nun | 南京法恩化学有限公司 | 2018-07-10 | — | — | CN | claimed |
| EP-2635562-B1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-09-03 | — | — | EP | claimed |
| EP-2635562-A1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-11 | — | — | EP | claimed |
| US-8524710-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | claimed |
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | claimed |
| WO-2012059507-A1 | PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-10 | — | — | WO | claimed |
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-05-10 | — | — | US | claimed |
| EP-2408745-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-01-25 | — | — | EP | claimed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | claimed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| EP-3798217-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | ARENA PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| US-20050282839-A1 | Pyrimidyl phosphonate antiviral compounds and methods of use | GILEAD SCIENCES, INC. | 2005-12-22 | — | — | US | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282839-A1 | Pyrimidyl phosphonate antiviral compounds and methods of use | TYMP, MTAP, PNP | HSD11B1 4655/4885APP 4726/4885CYP3A4 3229/4885 |
| US-20120115843-A1 | NOVEL PYRROLIDINE DERIVATIVES | CTSD, CTSV, CTSS | HSD11B1 3654/4885APP 448/4885CYP3A4 643/4885 |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | TYMP, PNP, PIKFYVE | HSD11B1 1716/4885APP 2820/4885CYP3A4 1961/4885 |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | HSD11B1 3638/4885APP 2525/4885CYP3A4 1349/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | HSD11B1 3497/4885APP 197/4885CYP3A4 2898/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | HSD11B1 1716/4885APP 2820/4885CYP3A4 1961/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | HSD11B1 3497/4885APP 197/4885CYP3A4 2898/4885 |
| US-20230033510-A1 | Compounds and Methods for Treatment of Visceral Pain | VIP, FABP2, FABP6 | HSD11B1 716/4885APP 4351/4885CYP3A4 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.